AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 133 min read$JNJ

Is Johnson & Johnson (JNJ) Overvalued After Q3 Earnings Miss? GF

Johnson & Johnson (JNJ) reported Q3 2026 sales of $25.4B, up 5.9% YoY, but net earnings dropped 95.9% to $210M due to litigation and acquisition costs. Adjusted EPS of $2.59 beat estimates. The company raised its 2026 sales and EPS guidance. GuruFocus values JNJ at $194.36, suggesting it is 35.7% overvalued.

Original reporting
gurufocus.com
Published Oct 13, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$JNJ
Bearish
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBearishHigh
01

Why it matters

The earnings release combines a sharp GAAP profit decline with an adjusted EPS beat and higher guidance, creating mixed market signals.

02

Market read

The earnings miss on GAAP EPS is likely to weigh on JNJ's stock today, though the raised guidance may cushion the decline.

03

What to watch

Insider selling of $154.9 M may signal internal concerns; the special charge for talc litigation resolution could be a one‑time hit.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Johnson & Johnson disclosed Q3 2026 results via an 8‑K filing, highlighting a special charge for talc litigation and acquisition costs, while raising full‑year sales and EPS guidance.

Company-level read

Ticker impact

$JNJBearishHigh confidence
Context

Q3 2026 earnings released with a 95.9% drop in GAAP EPS to $0.09 versus $2.12 a year ago and adjusted EPS of $2.59 beating estimates, plus raised 2026 guidance.

Expected impact

likely pressure as investors price in the large GAAP earnings miss despite higher guidance

Evidence & confidence

The stark GAAP EPS decline signals short‑term weakness, while the upward guidance may limit the downside, creating mixed sentiment and short‑term sell pressure.

Market effects

Sector

Healthcare sector may see modest pullback as a large cap reports a GAAP earnings miss, but the guidance raise could support peers with strong pipelines.

Regional

U.S. market may open lower in health‑care stocks, with JNJ leading the move.

Global

Limited to global health‑care investors; no broader macro impact.

Counterpoint

What could challenge this read

The adjusted earnings beat and raised guidance suggest the GAAP miss is a one‑off; a contrarian could look for a bounce.

Key entities

  • company
    Johnson & Johnson

    Diversified health‑care conglomerate reporting Q3 2026 results.

  • company
    Firefly Bio, Inc.

    Acquisition target contributing to special charges.

  • company
    Sail Biomedicines

    Strategic partner mentioned in the filing.

Read at source← All news

StoryJohnson & Johnson posts Q3 2026 results, lifts full‑year sales and earnings outlook

Also covered by

5 outlets

Related articles

OCT 13
$JNJHighAI 9/10

J&J Q3 2026 slides: $25.4B revenue, OTTAVA FDA win, margins pressured

Johnson & Johnson (JNJ) reported Q3 2026 revenue of $25.4B, up 5.9%, but shares fell 4.36% due to margin pressure. Adjusted EPS declined 7.5% YoY to $2.59. U.S. sales grew 9.1%, while international sales rose 1.8%. Innovative Medicine saw 7.9% growth, but MedTech lagged with 2.5% growth. The FDA approved the OTTAVA Robotic System, a new surgical robotics category. The company raised its full-year 2026 guidance.

investing.com2 min
OCT 13
$JNJHighAI 8/10

Johnson & Johnson Q3 2026 earnings: CEO and CFO prepared remarks

Johnson & Johnson reported Q3 2026 operational sales growth of 6%, exceeding analyst consensus. The company highlighted strong performance in Oncology, Immunology, and Neuroscience, with several key products driving growth. CEO Joaquin Duato expressed confidence in meeting annual guidance and exceeding $100 billion in revenue for the first time. MedTech segment grew 2.5%, with notable advancements in Cardiovascular and Surgery.

marketscreener.com2 min
OCT 13
$MUHighAI 8/10

5 Things to Know Before the Stock Market Opens on Tuesday

Stock futures are mixed as investors review earnings reports. UnitedHealth (UNH) shares rise after strong earnings, while memory stocks (MU, SNDK, SKHY) fall due to Chinese chipmaker breakthrough. JPMorgan (JPM), Wells Fargo (WFC), Citigroup (C), and Goldman Sachs (GS) report mixed results. Johnson & Johnson (JNJ) shares slip after missing estimates but raising full-year forecasts.

aol.com3 min
OCT 13
$JNJHighAI 9/10

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

JOHNSON & JOHNSON (JNJ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com For immediate release Johnson & Johnson reports Q3 2026 results, raises 2026 guidance • 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational grow

SEC EDGAR 8-K6 min